ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes

Neuroendocrinology

Volumn 95, Issue 2, 2012, Pages 98-119

  Jensen, Robert T ^a   Cadiot, Guillaume ^b   Brandi, Maria L ^c   De Herder, Wouter W ^d   Kaltsas, Gregory ^e   Komminoth, Paul ^f   Scoazec, Jean Yves ^g   Salazar, Ramon ^h   Sauvanet, Alain ^g   Kianmanesh, Reza ⁱ  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SERVICE DE DERMATOLOGIE   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF ATHENS   (Greece)

^f TRIEMLI HOSPITAL   (Switzerland)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CAPECITABINE; DACARBAZINE; DIAZOXIDE; DOXORUBICIN; EDOTREOTIDE; EPIRUBICIN; ESOMEPRAZOLE; EVEROLIMUS; FLUOROURACIL; KETOCONAZOLE; LANSOPRAZOLE; METYRAPONE; MIFEPRISTONE; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PREDNISOLONE; RABEPRAZOLE; RAPAMYCIN; SECRETIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; VERAPAMIL; YTTRIUM 90;

CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CUSHING DISEASE; DRUG DOSE INCREASE; DRUG MECHANISM; EDEMA; ENDOCRINE TUMOR; FOLLOW UP; GASTRIC HYPERACIDITY; GASTRINOMA; GENETIC ANALYSIS; GLUCAGONOMA; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; INSULINOMA; KIDNEY DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RARE FUNCTIONING TUMOR; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; TUMOR LOCALIZATION; VERNER MORRISON SYNDROME; WEIGHT GAIN; ZOLLINGER ELLISON SYNDROME;

HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84857867891     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000335591     Document Type: Review

References (224)

1. Oberg K: Pancreatic endocrine tumors. Semin Oncol 2010; 37: 594-618.
2. Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492.
3. Kulke MH, Anthony LB, Bushnell DL, et al: NANETS Treatment Guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735-752.
4. Ekeblad S: Islet cell tumours. Adv Exp Med Biol 2010; 654: 771-789.
5. O'Toole D, Salazar R, Falconi M, et al: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195. (Pubitemid 46361053)
6. Falconi M, Plockinger U, Kwekkeboom DJ, et al: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211. (Pubitemid 46361054)
7. Kaltsas G, Androulakis II, de Herder WW, et al: Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 2010; 17:R173-R193.
8. Jensen RT, Niederle B, Mitry E, et al: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182. (Pubitemid 46361051)
9. Ellison EC, Johnson JA: The Zollinger-Ellison syndrome: A comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46: 13-106.
10. Roy P, Venzon DJ, Shojamanesh H, et al: Zollinger-Ellison syndrome: Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411.
11. Jensen RT, Berna MJ, Bingham MD, et al: Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008; 113(suppl):1807-1843.
12. Gibril F, Schumann M, Pace A, et al: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1,009 patients from the literature. Medicine (Baltimore) 2004; 83: 43-83. (Pubitemid 38124855)
13. Vanderveen K, Grant C: Insulinoma. Cancer Treat Res 2010; 153: 235-252.
14. Guettier JM, Gorden P: Insulin secretion and insulin-producing tumors. Expert Rev Endocrinol Metab 2010; 5: 217-227.
15. De Herder WW, Niederle B, Scoazec JY, et al: Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 2006; 84: 183-188. (Pubitemid 46361052)
16. Anlauf M, Garbrecht N, Henopp T, et al: Sporadic versus hereditary gastrinomas of the duodenum and pancreas: Distinct clinicopathological and epidemiological features. World J 2006; 12: 5440-5446. (Pubitemid 44501800)
17. Kloppel G, Anlauf M: Gastrinoma -morphological aspects. Wien Klin Wochenschr 2007; 119: 579-584.
18. Gibril F, Jensen RT: Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 114-121. (Pubitemid 40796696)
19. Anlauf M, Perren A, Meyer CL, et al: Precursor lesions in patients with multiple endocrine neoplasia type 1 associated duodenal gastrinomas. Gastroenterology 2005; 128: 1187-1198. (Pubitemid 40712171)
20. Bosman FT, Carneiro F, Hruban RH, Theise ND: World Health Organization classification of tumors and genetics of the digestive system, ed 1. Lyon, IARC, 2010.
21. Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401. (Pubitemid 44451313)
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual, ed 1. New York, Springer, 2010.
23. Fischer L, Kleeff J, Esposito I, et al: Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008; 95: 627-635.
24. Ekeblad S, Skogseid B, Dunder K, et al: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
25. Pape UF, Jann H, Muller-Nordhorn J, et al: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
26. Zhao YP, Zhan HX, Zhang TP, et al: Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol 2011; 103: 169-174.
27. Casadei R, Ricci C, Rega D, et al: Pancreatic endocrine tumors less than 4 cm in diameter: Resect or enucleate? A single-center experience. Pancreas 2010; 39: 825-828.
28. Zerbi A, Falconi M, Rindi G, et al: Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010; 105: 1421-1429.
29. Niederle MB, Hackl M, Kaserer K, et al: Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-918.
30. Klimstra DS, Modlin IR, Coppola D, et al: The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707-712.
31. Weber HC, Venzon DJ, Lin JT, et al: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
32. Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 2007; 119: 573-578. (Pubitemid 350060665)
33. Thom AK, Norton JA, Axiotis CA, et al: Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991; 110: 1086-1093.
34. Stabile BE, Morrow DJ, Passaro E Jr: The gastrinoma triangle: Operative implications. Am J Surg 1984; 147: 25-31. (Pubitemid 14220378)
35. Pipeleers-Marichal M, Kloppel G: Gastrinomas in MEN-1. N Engl J Med 1990; 323: 349.
36. MacFarlane MP, Fraker DL, Alexander HR, et al: A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995; 118: 973-980.
37. Garbrecht N, Anlauf M, Schmitt A, et al: Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: Incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15: 229-241. (Pubitemid 351449742)
38. Isidori AM, Kaltsas GA, Grossman AB: Ectopic ACTH syndrome. Front Horm Res 2006; 35: 143-156. (Pubitemid 44024248)
39. Hoffmann KM, Furukawa M, Jensen RT: Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005; 19: 675-697. (Pubitemid 41614116)
40. Levy-Bohbot N, Merle C, Goudet P, et al: Prevalence, characteristics and prognosis of MEN-1-associated glucagonomas, VIPomas, and somatostatinomas: Study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004; 28: 1075-1081. (Pubitemid 39655853)
41. Yu F, Venzon DJ, Serrano J, et al: Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630. (Pubitemid 29075250)
42. Jensen RT: Natural history of digestive endocrine tumors; in Mignon M, Colombel JF (eds): Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, Libbey Eurotext, 1999, pp 192-219.
43. Gibril F, Venzon DJ, Ojeaburu JV, et al: Prospective study of the natural history of gastrinoma in patients with MEN1: Definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001; 86: 5282-5293. (Pubitemid 33070249)
44. Jensen RT: Zollinger-Ellison syndrome; in Doherty GM, Skogseid B (eds): Surgical Endocrinology: Clinical Syndromes. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 291-344.
45. Maton PN, Gardner JD, Jensen RT: Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315: 1-5.
46. Cadiot G, Vuagnat A, Doukhan I, et al: Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 1999; 116: 286-293. (Pubitemid 29055350)
47. Norton JA, Jensen RT: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773. (Pubitemid 39425767)
48. Goh BK, Chow PK, Tan YM, et al: Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: Results from a single institution experience with 61 surgically treated cases. ANZ J Surg 2011; 81: 79-85.
49. London JF, Shawker TH, Doppman JL, et al: Zollinger-Ellison syndrome: Prospective assessment of abdominal US in the localization of gastrinomas. Radiology 1991; 178: 763-767.
50. Mathur A, Gorden P, Libutti SK: Insulinoma. Surg Clin North Am 2009; 89: 1105-1121.
51. Jonkers YM, Claessen SM, Perren A, et al: DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocr Relat Cancer 2007; 14: 769-779. (Pubitemid 350074065)
52. Norton JA, Fang TD, Jensen RT: Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Cancer 2006; 4: 148-153. (Pubitemid 44265371)
53. Goudet P, Murat A, Cardot-Bauters C, et al: Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: A comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009; 33: 1197-1207.
54. Goudet P, Murat A, Binquet C, et al: Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34: 249-255.
55. Gibril F, Chen Y-J, Schrump DS, et al: Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88: 1066-1081. (Pubitemid 36337758)
56. Krenning EP, Bakker WH, Kooij PP, et al: Somatostatin receptor scintigraphy with indium-111-DTPA-D -Phe 1 -octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
57. Osefo N, Ito T, Jensen RT: Gastric acid hypersecretory states: Recent insights and advances. Curr Gastroenterol Rep 2009; 11: 433-441.
58. Berna MJ, Hoffmann KM, Serrano J, et al: Serum gastrin in Zollinger-Ellison syndrome. I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2,229 cases from the literature. Medicine (Baltimore) 2006; 85: 295-330. (Pubitemid 44772671)
59. Corleto VD, Annibale B, Gibril F, et al: Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 1555-1561. (Pubitemid 32912397)
60. Arnold R: Diagnosis and differential diagnosis of hypergastrinemia. Wien Klin Wochenschr 2007; 119: 564-569. (Pubitemid 350060659)
61. Roy P, Venzon DJ, Feigenbaum KM, et al: Gastric secretion in Zollinger-Ellison syndrome: Correlation with clinical expression, tumor extent and role in diagnosis -a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001; 80: 189-222. (Pubitemid 32466460)
62. Benya RV, Metz DC, Venzon DJ, et al: Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia type 1. Am J Med 1994; 97: 436-444. (Pubitemid 24345595)
63. Cadiot G, Houillier P, Allouch A, et al: Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison. Gut 1996; 39: 273-278. (Pubitemid 26276006)
64. Wynick D, Williams SJ, Bloom SR: Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 1988; 319: 605-607.
65. Chiang HC, O'Dorisio TM, Huang SC, et al: Multiple hormone elevations in patients with Zollinger-Ellison syndrome: Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 1990; 99: 1565-1575.
66. Vinik AI, Woltering EA, Warner RR, et al: NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39: 713-734.
67. O'Toole D, Grossman A, Gross D, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology 2009; 90: 194-202.
68. Rehfeld JF, Gingras MH, Bardram L, et al: The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140: 1444-1453.
69. Weber HC, Venzon DJ, Jensen RT, et al: Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology 1997; 112: 84-91. (Pubitemid 27008989)
70. Jensen RT: Consequences of long-term proton pump blockade: Highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19.
71. Oh DS, Wang HS, Ohning GV, et al: Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2006; 4: 1467-1473. (Pubitemid 44880025)
72. Berna MJ, Hoffmann KM, Long SH, et al: Serum gastrin in Zollinger-Ellison syndrome. II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85: 331-364. (Pubitemid 44772672)
73. Mignon M, Jais P, Cadiot G, Yedder D, Vatier J: Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome; in Mignon M, Jensen RT (eds): Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series. Front Gastrointest Res. Basel, Karger, 1995, vol 23, pp 223-239.
74. Frucht H, Howard JM, Slaff JI, et al: Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: A prospective study. Ann Intern Med 1989; 111: 713-722. (Pubitemid 19266110)
75. Gibril F, Jensen RT: Zollinger-Ellison syndrome revisited: Diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004; 6: 454-463. (Pubitemid 39591825)
76. Goldman JA, Blanton WP, Hay DW, et al: Case report: False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009; 7: 600-602.
77. Niederle B: Hypergastrinemia -diagnosis and treatment. Wien Klin Wochenschr 2007; 119: 561-563.
78. De Herder WW, O'Toole D, Rindi G, et al: ENETS consensus guidelines for the management of patients with digestive neuroendocrine tumors. Part 1. Stomach, duodeneum and pancreas. Neuroendocrinology 2006; 84: 151-216.
79. Berna MJ, Annibale B, Marignani M, et al: A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: Identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-1591. (Pubitemid 351656492)
80. Norton JA, Cornelius MJ, Doppman JL, et al: Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome and multiple endocrine neoplasia type I: A prospective study. Surgery 1987; 102: 958-966. (Pubitemid 18010741)
81. Waldmann J, Fendrich V, Habbe N, et al: Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): A critical analysis of its value. World J Surg 2009; 33: 1208-1218.
82. Norton JA, Venzon DJ, Berna MJ, et al: Prospective study of surgery for primary hyperaparathyroidism in multiple endocrine neoplasia type 1, and Zollinger-Ellison syndrome: Long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247: 501-510.
83. Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488. (Pubitemid 28312244)
84. Brandi ML, Gagel RF, Angeli A, et al: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671. (Pubitemid 33152604)
85. Thakker RV: Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010; 24: 355-370.
86. Service FJ, Natt N, Thompson GB, et al: Noninsulinoma pancreatogenous hypoglycemia: A novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999; 84: 1582-1589. (Pubitemid 30644258)
87. Marsk R, Jonas E, Rasmussen F, et al: Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia 2010; 53: 2307-2311.
88. Patti ME, Goldfine AB: Hypoglycaemia following gastric bypass surgery -diabetes remission in the extreme? Diabetologia 2010; 53: 2276-2279.
89. Van Bon AC, Benhadi N, Endert E, et al: Evaluation of endocrine tests. D: The prolonged fasting test for insulinoma. Neth J Med 2009; 67: 274-278.
90. Hirshberg B, Livi A, Bartlett DL, et al: Forty-eight-hour fast: The diagnostic test for insulinoma. J Clin Endocrinol Metab 2000; 85: 3222-3226.
91. Vezzosi D, Bennet A, Fauvel J, et al: Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 2007; 157: 75-83. (Pubitemid 47162569)
92. Sundin A, Vullierme MP, Kaltsas G, et al: ENETS guidelines for the standards of care in patients with neuroendocrine tumours: Radiological examinations in patients with neuroendocrine tumours. Neuroendocrinology 2009; 90: 183.
93. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with 111 In-pentetreotide. Neuroendocrinology 2009; 90: 184-189.
94. Sundin A, Garske U, Orlefors H: Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85. (Pubitemid 46421900)
95. Rockall AG, Reznek RH: Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43-68. (Pubitemid 46436731)
96. Morrow EH, Norton JA: Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am 2009; 89: 1091-1103.
97. Fraker DL, Norton JA, Alexander HR, et al: Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320-330. (Pubitemid 24313225)
98. Norton JA, Fraker DL, Alexander HR, et al: Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419.
99. Norton JA, Alexander HR, Fraker DL, et al: Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004; 239: 617-626. (Pubitemid 38525632)
100. Lebtahi R, Cadiot G, Sarda L, et al: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853-858. (Pubitemid 27251972)
101. Doppman JL, Miller DL, Chang R, et al: Gastrinomas: Localization by means of selective intraarterial injection of secretin. Radiology 1990; 174: 25-29. (Pubitemid 20017077)
102. Termanini B, Gibril F, Reynolds JC, et al: Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-347. (Pubitemid 27078820)
103. Alexander HR, Fraker DL, Norton JA, et al: Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238. (Pubitemid 30191719)
104. Anderson MA, Carpenter S, Thompson NW, et al: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95: 2271-2277.
105. Ruszniewski P, Amouyal P, Amouyal G, et al: Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635.
106. Patel KK, Kim MK: Neuroendocrine tumors of the pancreas: Endoscopic diagnosis. Curr Opin Gastroenterol 2008; 24: 638-642.
107. Guettier JM, Kam A, Chang R, et al: Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: The NIH experience. J Clin Endocrinol Metab 2009; 94: 1074-1080.
108. Morganstein DL, Lewis DH, Jackson J, et al: The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol 2009; 19: 2467-2473.
109. Gibril F, Reynolds JC, Doppman JL, et al: Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study. Ann Intern Med 1996; 125: 26-34.
110. Gibril F, Jensen RT: Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36:S106-S120. (Pubitemid 41115498)
111. Akerstrom G, Hellman P: Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109. (Pubitemid 46421901)
112. Srirajaskanthan R, Kayani I, Quigley AM, et al: The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111 In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882.
113. Putzer D, Gabriel M, Henninger B, et al: Bone metastases in patients with neuroendocrine tumor: 68 Ga-DOTA-Tyr 3 -octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214-1221.
114. Ambrosini V, Nanni C, Zompatori M, et al: 68 Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010; 37: 722-727.
115. Dudczak R, Traub-Weidinger T: PET and PET/CT in endocrine tumours. Eur J Radiol 2010; 73: 481-493.
116. Buchmann I, Henze M, Engelbrecht S, et al: Comparison of 68 Ga-DOTATOC PET and 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626. (Pubitemid 47476920)
117. Gabriel M, Decristoforo C, Kendler D, et al: 68 Ga-DOTA-Tyr 3 -octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518. (Pubitemid 47571404)
118. Ruf J, Heuck F, Schiefer J, et al: Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010; 91: 101-109.
119. Cadiot G, Lebtahi R, Sarda L, et al: Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111: 845-854. (Pubitemid 26327587)
120. Dromain C, De Baere T, Lumbroso J, et al: Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23: 70-78. (Pubitemid 41702624)
121. Gibril F, Doppman JL, Reynolds JC, et al: Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998; 16: 1040-1053. (Pubitemid 28108739)
122. Lebtahi R, Cadiot G, Delahaye N, et al: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: Bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999; 40: 1602-1608. (Pubitemid 29471148)
123. Bhate K, Mok WY, Tran K, et al: Functional assessment in the multimodality imaging of pancreatic neuroendocrine tumours. Minerva Endocrinol 2010; 35: 17-25.
124. Thomas-Marques L, Murat A, Delemer B, et al: Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266-273. (Pubitemid 43381666)
125. Triponez F, Goudet P, Dosseh D, et al: Is surgery beneficial for MEN1 patients with small ( ! or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662. (Pubitemid 43724090)
126. Figueiredo FA, Giovannini M, Monges G, et al: Pancreatic endocrine tumors: A large single-center experience. Pancreas 2009; 38: 936-940.
127. Christ E, Wild D, Forrer F, et al: Glucagonlike peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009; 94: 4398-4405.
128. Kauhanen S, Seppanen M, Minn H, et al: Clinical PET imaging of insulinoma and β -cell hyperplasia. Curr Pharm Des 2010; 16: 1550-1560.
129. Chetty R: An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. Arch Pathol Lab Med 2008; 132: 1285-1289.
130. Kloppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31. (Pubitemid 46421903)
131. Kloppel G, Couvelard A, Perren A, et al: ENETS guidelines for the standards of care in patients with neuroendocrine tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 166.
132. Capelli P, Martignoni G, Pedica F, et al: Endocrine neoplasms of the pancreas: Pathologic and genetic features. Arch Pathol Lab Med 2009; 133: 350-364.
133. Schmitt AM, Anlauf M, Rousson V, et al: WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007; 31: 1677-1682. (Pubitemid 350287565)
134. Scarpa A, Mantovani W, Capelli P, et al: Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.
135. La Rosa S, Klersy C, Uccella S, et al: Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40: 30-40.
136. Casadei R, Ricci C, Pezzilli R, et al: Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: Results of a single-center series. World J Surg 2009; 33: 2458-2463.
137. Klimstra DS, Modlin IR, Adsay NV, et al: Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34: 300-313.
138. Walker FM, Lehy T, Bernuau DG, et al: Detection of gastrin mRNA in human antral mucosa and digestive endocrine tumors by in situ hybridization: A correlative study with immunocytochemistry and electron microscopy. J Histochem Cytochem 1992; 40: 1363-1372.
139. Toumpanakis CG, Caplin ME: Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008; 103: 729-732. (Pubitemid 351406008)
140. Anlauf M, Bauersfeld J, Raffel A, et al: Insulinomatosis: A multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 2009; 33: 339-346.
141. Henopp T, Anlauf M, Schmitt A, et al: Glucagon cell adenomatosis: A newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab 2009; 94: 213-217.
142. Fendrich V, Waldmann J, Bartsch DK, et al: Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009; 6: 419-428.
143. Zerbi A, Capitanio V, Boninsegna L, et al: Surgical treatment of pancreatic endocrine tumours in Italy: Results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg 2011; 396: 313-321.
144. Abood GJ, Go A, Malhotra D, et al: The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009; 89: 249-266, x.
145. Lorenz K, Dralle H: Surgical treatment of sporadic gastrinoma. Wien Klin Wochenschr 2007; 119: 597-601. (Pubitemid 350060663)
146. Bartsch DK, Langer P, Rothmund M: Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1. Wien Klin Wochenschr 2007; 119: 602-608. (Pubitemid 350060664)
147. Norton JA, Fraker DL, Alexander HR, et al: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644. (Pubitemid 29399042)
148. Tonelli F, Fratini G, Nesi G, et al: Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244: 61-70. (Pubitemid 44297449)
149. Norton JA, Alexander HR, Fraker DL, et al: Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-506. (Pubitemid 32946712)
150. Franz RC, Penzhorn HO: Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome? S Afr J Surg 2007; 45: 58-60.
151. Fishbeyn VA, Norton JA, Benya RV, et al: Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: The best approach. Ann Intern Med 1993; 119: 199-206. (Pubitemid 23327619)
152. Steinmuller T, Kianmanesh R, Falconi M, et al: Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62. (Pubitemid 350308294)
153. Sugg SL, Norton JA, Fraker DL, et al: A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993; 218: 138-144. (Pubitemid 23229139)
154. Grobmyer SR, Vogel SB, McGuigan JE, et al: Reoperative surgery in sporadic Zollinger-Ellison Syndrome: Long-term results. J Am Coll Surg 2009; 208: 718-722.
155. Norton JA, Alexander HA, Fraker DL, et al: Possible primary lymph node gastrinomas: Occurrence, natural history and predictive factors: A prospective study. Ann Surg 2003; 237: 650-659. (Pubitemid 38174531)
156. Norton JA, Jensen RT: Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 2007; 205:S34-S37. (Pubitemid 47488912)
157. Fendrich V, Langer P, Waldmann J, et al: Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 2007; 94: 1331-1341. (Pubitemid 350144380)
158. Fernandez-Cruz L, Blanco L, Cosa R, et al: Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32: 904-917.
159. Espana-Gomez MN, Velazquez-Fernandez D, Bezaury P, et al: Pancreatic insulinoma: A surgical experience. World J Surg 2009; 33: 1966-1970.
160. Richards ML, Thompson GB, Farley DR, et al: Setting the bar for laparoscopic resection of sporadic insulinoma. World J Surg 2011; 35: 785-789.
161. Isla A, Arbuckle JD, Kekis PB, et al: Laparoscopic management of insulinomas. Br J Surg 2009; 96: 185-190.
162. Krudy AG, Doppman JL, Jensen RT, et al: Localization of islet cell tumors by dynamic CT: Comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol 1984; 143: 585-589. (Pubitemid 14067875)
163. Gimm O, Konig E, Thanh PN, et al: Intraoperative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection. Langenbecks Arch Surg 2007; 392: 679-684. (Pubitemid 47620342)
164. Elias D, Goere D, Leroux G, et al: Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009; 35: 1092-1097.
165. Fendrich V, Michl P, Habbe N, et al: Liverspecific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2: 367-373.
166. Kianmanesh R, Sauvanet A, Hentic O, et al: Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: A safe approach for radical resection. Ann Surg 2008; 247: 659-665. (Pubitemid 351440617)
167. Hodul P, Malafa M, Choi J, et al: The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control 2006; 13: 61-71. (Pubitemid 43327556)
168. Desai KK, Khan MS, Toumpanakis C, et al: Management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Minerva Gastroenterol Dietol 2009; 55: 425-443.
169. Reddy SK, Clary BM: Neuroendocrine liver metastases. Surg Clin North Am 2010; 90: 853-861.
170. Akyildiz HY, Mitchell J, Milas M, et al: Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: Long-term follow-up. Surgery 2010; 148: 1288-1293.
171. Modlin IM, Pavel M, Kidd M, et al: Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
172. Nieto JM, Pisegna JR: The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006; 7: 169-175. (Pubitemid 43263256)
173. Auernhammer CJ, Goke B: Medical treatment of gastrinomas. Wien Klin Wochenschr 2007; 119: 609-615. (Pubitemid 350060658)
174. Baldwin CM, Keam SJ: Rabeprazole: A review of its use in the management of gastric acid-related diseases in adults. Drugs 2009; 69: 1373-1401.
175. Wilcox CM, Hirschowitz BI: Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother 2009; 10: 1145-1157.
176. Metz DC, Sostek MB, Ruszniewski P, et al: Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648-2654. (Pubitemid 350179329)
177. Morocutti A, Merrouche M, Bjaaland T, et al: An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther 2006; 24: 1439-1444. (Pubitemid 44657120)
178. Metz DC, Comer GM, Soffer E, et al: Threeyear oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006; 23: 437-444. (Pubitemid 43382024)
179. Yang YX, Metz DC: Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115-1127.
180. Ito T, Jensen RT: Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B 12 , iron, and magnesium. Curr Gastroenterol Rep 2010; 12: 448-457.
181. Termanini B, Gibril F, Sutliff VE III, et al: Effect of long-term gastric acid suppressive therapy on serum vitamin B 12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104: 422-430. (Pubitemid 28274845)
182. Ojeaburu JV, Ito T, Crafa P, et al: Mechanism of acid hypersecretion post-curative gastrinoma resection. Dig Dis Sci 2011; 56: 139-154.
183. Pisegna JR, Norton JA, Slimak GG, et al: Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767-778.
184. Maton PN, Frucht H, Vinayek R, et al: Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: A prospective study. Gastroenterology 1988; 94: 294-299. (Pubitemid 18054764)
185. Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757-767. (Pubitemid 40744545)
186. Kulke MH, Bergsland EK, Yao JC: Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360: 195-197.
187. Bourcier ME, Sherrod A, DiGuardo M, et al: Successful control of intractable hypoglycemia using rapamycin in an 86-yearold man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 2009; 94: 3157-3162.
188. Ong GS, Henley DE, Hurley D, et al: Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010; 162: 1001-1008.
189. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973. (Pubitemid 39004355)
190. Fazio N, de Braud F, Delle Fave G, et al: Interferon-α and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: Single agent or combination? Ann Oncol 2007; 18: 13-19. (Pubitemid 46152493)
191. Petrossians P, Thonnard AS, Beckers A: Medical treatment in Cushing's syndrome: Dopamine agonists and cabergoline. Neuroendocrinology 2010; 92(suppl 1):116-119.
192. Castinetti F, Conte-Devolx B, Brue T: Medical treatment of Cushing's syndrome: Glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 2010; 92(suppl 1):125-130.
193. Pivonello R, Ferone D, Lamberts SW, et al: Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005; 352: 2457-2458. (Pubitemid 40958451)
194. Feelders RA, Hofland LJ, de Herder WW: Medical treatment of Cushing's syndrome: Adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010; 92(suppl 1):111-115.
195. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al: ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95: 157-176.
196. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al: Octreotide versus octreotide plus interferon in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771. (Pubitemid 41116728)
197. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al: International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696. (Pubitemid 46606312)
198. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al: Predictive factors of efficacy of the somatostatin analogue octreotide as first-line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13: 1213-1221. (Pubitemid 46212575)
199. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, et al: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004; 40: 515-520. (Pubitemid 38220767)
200. Fjallskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK: Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 53-58. (Pubitemid 352009119)
201. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao J: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22 4762-4771.
202. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523.
203. Walter T, Bruneton D, Cassier PA, et al: Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer 2010; 9: 248-254.
204. Strosberg JR, Fine RL, Choi J, et al: Firstline chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
205. Auernhammer CJ, Goke B: Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011; 60: 1009-1021.
206. Vogl TJ, Naguib NN, Zangos S, et al: Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517-528.
207. Nazario J, Gupta S: Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol 2010; 37: 118-126.
208. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP: Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010; 40: 78-88.
209. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al: Treatment with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
210. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al: 90 Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-1659.
211. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
212. Plockinger U, Wiedenmann B: Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 553-576. (Pubitemid 41447718)
213. Khasraw M, Gill A, Harrington T, et al: Management of advanced neuroendocrine tumors with hepatic metastasis. J Clin Gastroenterol 2009; 43: 838-847.
214. Shah T, Caplin M: Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 617-636. (Pubitemid 41447722)
215. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al: Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19: 595-616. (Pubitemid 41447721)
216. Toumpanakis C, Meyer T, Caplin ME: Cytotoxic treatment including embolization/ chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 131-144. (Pubitemid 46421904)
217. Eriksson J, Stalberg P, Nilsson A, et al: Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32: 930-938.
218. King J, Quinn R, Glenn DM, et al: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929.
219. Oberg KE, Reubi JC, Kwekkeboom DJ, et al: Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010; 139: 742-753, 753.e1.
220. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.
221. Arnold R, Chen YJ, Costa F, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Follow-up and documentation. Neuroendocrinology 2009; 90: 227-233.
222. Poitras P, Gingras MH, Rehfeld JF: The Zollinger-Ellison syndrome: Dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012; 10: 199-202.
223. Raymond E, Dahan L, Raoul, JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
224. Jensen RT, Delle Fave G: Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011; 364: 564-565.